Navigation Links
Innovative Drugs to Transform European Alzheimer's Disease Medication Market by 2015, Says Frost & Sullivan
Date:11/14/2012

LONDON, Nov. 14, 2012 /PRNewswire/ -- The patent expiry of all four existing EMEA approved drugs for Alzheimer's disease (AD) by 2015 is likely to cause a steep decline in the growth of the European AD medication market. However, the approval of next generation therapies that can delay disease progression and restore cognitive functions are expected to revive opportunities in the market from 2015 to 2018.

New analysis from Frost & Sullivan (http://www.healthcare.frost.com), European Alzheimer's Disease Medication Market, estimates the market to earn $1.80 billion in 2012 and reach $4.78 billion in 2019, growing at a compound annual growth rate (CAGR) of 15.1% from 2012-2019.

"Increasing R&D activity and a strong pipeline of disease modifying drugs bode well for market expansion," notes Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram. "Considerable unexplored opportunities and the commercial goldmine that is the AD medication market have motivated several pharmaceutical and biotechnology companies to invest in R&D, particularly targeting the moderate-to-severe patient group."

Existing drug classes for AD offer poor therapeutic efficacy. The core focus of new R&D approaches has therefore centered on novel disease modifying drugs.

"These drugs are expected to offer potential benefits over conventional therapeutic options as they are safer, more effective and aim to prevent or slow down disease progression rather than provide just symptomatic relief," adds Chidambaram. "Therefore, these new drugs are expected to command premium prices and fuel market growth."

A key challenge at present is the looming patent expiry of key blockbuster drugs including Aricept, Exelon Patch and Ebixa. Their going off-patent is set to unleash a flood of cheaper generic equivalents that will result in lowered market revenues.

The accurate diagnosis of AD, especially in the early stages and monitoring of disease progression, will play a vital role in promoting proper market segmentation and positioning of drugs by market participants.

AD diagnostics and therapeutics go hand-in-hand. Although the development and approval of new, improved diagnostic tools over a period of time has been a boon to the AD market, the levels of unmet need still remain high.

"The commercialization of the extensively researched advanced diagnostic technologies targeting phosphorylated tau protein and A-beta 42 could open new market opportunities," concludes Chidambaram. "They not only help patients gain treatment access in the initial stages, but also significantly improve the clinical trial experience."

If you are interested in more information on this study, please send an email with your contact details to Anna Zanchi, Corporate Communications, at anna.zanchi@frost.com.

European Alzheimer's Disease Medication Market is part of the Life Sciences Growth Partnership Service programme, which also includes research in the following markets: U.S Alzheimer's Disease Medication Market and Analysis of the European Bipolar Disorder Therapeutics Market, among others. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion
Join Us:           Join our community
Subscribe:       Newsletter on "the next big thing"
Register:         Gain access to visionary innovation

Contact
Anna Zanchi
Corporate Communications – Europe
P: 0039 02 48516133
E: anna.zanchi@frost.com
http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Coloplast Launches the Innovative Altis Single Incision Sling System
2. DebMed Selected By Three Leading Healthcare Group Purchasing Organizations To Demonstrate Innovative Patient Safety Solution
3. The Japanese Cancer Association and Debiopharm Group Present Doctors Oshima and Tanaka with the 2012 JCA-Mauvernay Award for their Innovative and Outstanding Cancer Research
4. Tranzbyte Corporation Acquires the Exclusive Right to Market Low-Cost, Innovative MRI machines in North and South America
5. Ixonos Provides NHS Choices With Innovative Health Apps
6. Pomona Valley Hospital is First in the Region to Use Innovative Technology for Neonates
7. New Jersey Health Foundation Initiates Program To Spur Innovative Research
8. Mylan Launches Commercial Operations in India, Starting with a Broad, Innovative Portfolio of ARV Products to Treat HIV/AIDS
9. CVS Caremark Charitable Trust Partners with National Association of Community Health Centers to Create Innovative Grant Program Focused on Managing Chronic Disease
10. Dr. Milton Owens, Well Known Bariatric Surgeon, Introduces Innovative "Inverted Corner Gastric Sleeve technique," An advanced technique that makes weight loss surgery even safer
11. Synapse Develops Technology for Innovative Asthma Management Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):